Gene-Silencing Pesticides Pose New Risks to Health, Environment and Farmers
By Eva Sirinathsinghji, Kendra Klein and Dana Perls,
Friends of the Earth
| 10. 06. 2020
WASHINGTON — “Gene-silencing pesticides” now under development pose unique risks to surrounding ecosystems and beneficial insects, including bees, according to a new report, released today by Friends of the Earth and Dr. Eva Sirinathsinghji. The report summarizes the gaps in research on experimental gene-silencing pesticides and the risks they pose to human health, the environment, and farmers.
Several biotech and agrichemical companies are moving quickly to patent and bring gene-silencing pesticides to market. Corporations including Bayer [OTCMKTS: BAYRY], BASF [OTCMKTS: BASFY], and Syngenta [owned by Sinochem-ChemChina], are using genetic engineering to develop the new pesticide sprays that exploit a cellular process called RNA interference (RNAi), in order to switch off or “silence” genes that are essential for the survival of insects — thus killing them.
The first gene-silencing pesticide spray is slated to be submitted to the U.S. EPA for registration by the end of this year. The product, developed by GreenLight Biosciences, targets the Colorado potato beetle. The spray is designed to be applied to crop leaves. When a beetle eats the contaminated leaves, genetic material enters the...
Related Articles
By Carl Zimmer, The New York Times | 10.20.2026
For the first time, scientists say they have used viruses designed by artificial intelligence to treat a human patient.
Researchers announced on Tuesday that they had administered the virus, known as a phage, to a patient suffering from a deadly...
By Noah Fromson, HealthLab | 10.19.2026
Gene therapy is no longer the future of medicine — it’s reality. Treatments that replace, silence or edit genes are already changing clinical care.
There are more than 6,000 rare genetic disorders but only a fraction currently have treatable targets...
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...